Literature DB >> 7199322

[Pharmacokinetics of midazolam after i.v. administration (author's transl)].

R Amrein, J P Cano, M Eckert, P Coassolo.   

Abstract

8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a] [1,4] benzodiazepine (midazolam, Ro 21-3981, Dormicum) is a special type of benzodiazepine. Its salts are water-soluble and also stable in an aqueous solution. Following i.v. injection of the substance, the human body eliminates midazolam almost entirely by means of biotransformation. Following rapid i.v. injection of midazolam into 8 normal volunteers, the plasma concentration of the substance decreases to approximately 10% within 1 h owing to a rapid rate of distribution. The biological half-life in the terminal phase (beta) ranges between 1 1/2 and 2 1/2 h. In view of the non-dose-dependent clearance and the various phases of distribution, the pharmacokinetic behaviour of the drug can be described by means of a linear three-compartmental model. The portion of drug extracted by the liver ranges between 40 and 50%, which implies a liver first-pass effect of approximately 50% after oral administration. The total plasma clearance is 300-350 ml/min. The absorption rate after i.m. injection is extremely rapid, with complete absorption taking place.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7199322

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  12 in total

1.  Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration.

Authors:  G Roncari; W H Ziegler; T W Guentert
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

2.  [Analytic data of the new benzodiazepine derivative midazolam (Dormicum) and its metabolites].

Authors:  H Schütz
Journal:  Z Rechtsmed       Date:  1985

3.  Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects.

Authors:  R Jochemsen; J G Wesselman; C J van Boxtel; J Hermans; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

4.  CSF penetration and pharmacokinetics of midazolam.

Authors:  S Sjövall; J Kanto; J J Himberg; M Hovi-Viander; M Salo
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration.

Authors:  R Jochemsen; J G Wesselman; J Hermans; C J van Boxtel; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

6.  Assay of midazolam and brotizolam in plasma by a gas chromatographic and a radioreceptor technique.

Authors:  R Jochemsen; P A Van Rijn; T G Hazelzet; D D Breimer
Journal:  Pharm Weekbl Sci       Date:  1983-12-16

7.  Pharmacokinetics of midazolam in the aged.

Authors:  M T Smith; V Heazlewood; M J Eadie; T O Brophy; J H Tyrer
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites.

Authors:  W H Ziegler; E Schalch; B Leishman; M Eckert
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

9.  Hypnotic efficacy and safety of midazolam and oxazepam in hospitalized female patients.

Authors:  R Fischbach
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

10.  Comparative clinical studies with midazolam, oxazepam and placebo.

Authors:  C Feldmeier; W Kapp
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.